The CONFORM Pivotal Trial
An Evaluation of the Safety and Effectiveness of the Conformal CLAAS System for Left Atrial Appendage Occlusion
Conformal Medical, Inc
1,600 participants
May 26, 2022
INTERVENTIONAL
Conditions
Summary
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
CLAAS
WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
Locations(83)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05147792